RICKMANSWORTH, England, April 8, 2014 /PRNewswire/ --
The European Commission has awarded a 1.3M Euro ($1.8M) grant to an international consortium to evaluate a ground-breaking cancer imaging technology. The imaging technology, termed Cerenkov Luminescence Imaging, has the potential to detect cancer during surgery and help ensure that all of the cancerous tissue is removed.
The two-year project entitled CLIO will evaluate the imaging technology in patients undergoing surgery for gastric cancer. Lightpoint Medical will conduct the clinical trial together with partners CROmed Research, Sagentia, ABX CRO, the Frédéric Joliot-Curie National Research Institute for Radiobiology and Radiation Health, and Semmelweis University, First Department of Surgery. The grant was awarded by the 7th Framework Program of the European Commission.
Ian Quirk, Director of Clinical and Regulatory Affairs at Lightpoint Medical commented "At Lightpoint we're excited to be a part of a collaboration involving such high calibre collaborators in this Framework Program 7 project, kindly funded by the European Commission. Significantly improving outcomes in cancer surgery at the core of everything Lightpoint strives to achieve and this project offer the opportunity to apply that ethos to gastric cancer."
About Lightpoint Medical
Lightpoint Medical is a medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's molecular imaging technology, based on Cerenkov luminescence imaging, has the potential to detect cancer in real-time during surgery, providing more accurate cancer treatment while sparing healthy tissue. For more information contact email@example.com or visit http://www.lightpointmedical.com
FP7 is the EU's main instrument for supporting innovative research in Europe, and has two main strategic objectives: to strengthen the scientific and technological base of European industry and to encourage its international competitiveness, while promoting research that supports EU policies. For more information visit http://cordis.europa.eu/fp7
SOURCE Lightpoint Medical